...
首页> 外文期刊>Pathology Research and Practice >Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues
【24h】

Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues

机译:正常和赘生性乳腺组织中免疫组化ERα,ERβ和ERβcx表达的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Estrogen receptor alpha (ERα) is a well-established prognostic marker in breast cancer. The role of estrogen receptor beta (ERβ) in breast cancers is still under investigation. We aimed to investigate the clinicopathological significance and immunohistochemical expression patterns of ERα, total ERβ (ERβ) and its spliced variant ERβcx in normal breast, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC).Our study population comprised 10 normal breasts, 26 DCISs and 44 IDCs. Immunohistochemical expression of these markers was investigated in sections of formalin-fixed, paraffin-embedded blocks by 2 observers.In invasive ductal carcinomas, ERβ expression had a significant positive correlation with ERα expression (p=0.013), while ERβcx expression was significantly associated with the presence of lymphovascular invasion (p=0.046). There was a significant relationship between ERα expression and low histological grade (p<0.0001). Similarly, ERα+/ERβ+ tumors (p=0.004) and ERα+/ERβcx+ tumors (p=0.008) were significantly associated with low histological grade, too. ERα expression (p=0.009), ERβcx expression (p=0.048) and ERα+/ERβ+ coexpression (p=0.002) increased significantly in progression from normal breast to invasive ductal carcinoma.Expression of ERα correlates with less aggressive phenotypic features, and ERβ expression is positively correlated with ERα expression in breast cancer. ERβcx is associated with aggressive features and can take part in the progression of invasive carcinoma. Increase in ERα+/ERβ+ coexpression, ERα expression and ERβcx expression in breast cancer progression indicates an enhancement in ER expressions or an alteration in expression patterns of different ER variants during mammary carcinogenesis.
机译:雌激素受体α(ERα)是乳腺癌中公认的预后标志物。雌激素受体β(ERβ)在乳腺癌中的作用仍在研究中。我们旨在研究ERα,总ERβ(ERβ)及其剪接变体ERβcx在正常乳腺,原位导管癌(DCIS)和浸润性导管癌(IDC)中的临床病理学意义和免疫组织化学表达模式。我们的研究人群包括10例正常乳腺,26个DCIS和44个IDC。由两名观察者在福尔马林固定,石蜡包埋的切片中研究了这些标志物的免疫组织化学表达。在浸润性导管癌中,ERβ表达与ERα表达显着正相关(p = 0.013),而ERβcx表达与ERα表达显着相关淋巴管浸润的存在(p = 0.046)。 ERα表达与低组织学分级之间存在显着相关性(p <0.0001)。同样,ERα+ /ERβ+肿瘤(p = 0.004)和ERα+ /ERβcx+肿瘤(p = 0.008)也与低组织学分级显着相关。从正常乳腺癌到浸润性导管癌的进展中,ERα表达(p = 0.009),ERβcx表达(p = 0.048)和ERα+ /ERβ+共表达(p = 0.002)明显增加。ERα的表达与侵袭性表型特征相关,并且乳腺癌中ERβ的表达与ERα的表达呈正相关。 ERβcx与侵袭性特征相关,可以参与浸润性癌的发展。乳腺癌进展过程中ERα+ /ERβ+共表达,ERα表达和ERβcx表达的增加表明在乳腺癌致癌过程中ER表达增强或不同ER变体的表达模式改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号